Does remifentanil attenuate renal ischemia-reperfusion injury better than dexmedetomidine in rat kidney?

Creative Commons License

Erkilic E., Kesimci E., Alaybeyoglu F., Kilinc I., Tural R., Yazgan A., ...More

DRUG DESIGN DEVELOPMENT AND THERAPY, vol.11, pp.677-683, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11
  • Publication Date: 2017
  • Doi Number: 10.2147/dddt.s126701
  • Journal Name: DRUG DESIGN DEVELOPMENT AND THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.677-683
  • Keywords: ischemia-reperfusion, dexmedetomidine, remifentanil, neutrophil gelatinase-associated lipocalin, GELATINASE-ASSOCIATED LIPOCALIN, ISCHEMIA/REPERFUSION INJURY, INFLAMMATORY RESPONSES, BIOMARKERS, PROTECTS, SURGERY, ANESTHESIA, INFUSION, SURVIVAL, OUTCOMES
  • Gazi University Affiliated: Yes

Abstract

Background: Ischemia-reperfusion (I/R) injury is a common cause of patient morbidity and mortality in the perioperative period. Patients undergoing long-lasting, abdominal, and urogenital surgeries with risk factors such as advanced age, peripheral artery disease, diabetes mellitus, renovascular disease, and congestive heart failure are candidates for acute kidney injury (AKI) due to impaired renal perfusion and decreased functional renal reserve. Pharmacological agents with multiple functions and anti-oxidative and anti-inflammation properties may be promising preventative strategies for AKI. Recently, dexmedetomidine (dex) has been postulated to have renoprotective effects.